newsfilter
← Latest News
Business Wire·

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

MRK
  • Merck & Co. reported third-quarter 2026 total worldwide sales of $18.1 billion, representing 5% growth (4% ex-FX).
  • KEYTRUDA/KEYTRUDA QLEX sales reached $8.6 billion with 6% growth, including $830 million from KEYTRUDA QLEX.
  • WINREVAIR sales grew 93% to $694 million, driven by U.S. demand and international launch uptake.
  • Animal Health sales increased 4% to $1.7 billion, with growth across both Livestock and Companion Animal portfolios.
  • GAAP EPS was $2.04, while Non-GAAP EPS was $2.49; both figures include a $0.12 per share one-time charge for a SciBrunch license agreement.
  • The company announced FDA acceptance of a BLA for sac-TMT for endometrial cancer based on Phase 3 TroFuse-005 trial data.
  • Positive Phase 3 results were presented for INTerpath-001, evaluating intismeran autogene plus KEYTRUDA for melanoma.
  • Positive Phase 2b results were reported for tulisokibart in moderate to severe hidradenitis suppurativa.
  • Full-year 2026 sales outlook was raised and narrowed to a range of $66.8 billion to $67.3 billion.
  • Full-year 2026 Non-GAAP EPS outlook was raised to a range of $2.77 to $2.82, incorporating the $0.12 SciBrunch charge.
  • R&D expenses for the quarter were $4.5 billion, a 7% increase from the prior year, driven by the SciBrunch charge and clinical development spending.
  • The company entered an exclusive global license agreement with SciBrunch for the investigational oral KRAS G12D inhibitor SPR2015.
  • The FDA approved WELIREG plus Lenvima for previously treated adult patients with advanced renal cell carcinoma.
  • The FDA accepted a supplemental BLA for ENFLONSIA to expand its indication to children under 2 years at risk for severe RSV.
  • The company announced the voluntary withdrawal of the BLA for ifinatamab deruxtecan for extensive-stage small cell lung cancer.